

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

110186.547

APPLICATION NO.

09/589,870

**FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Stephen C. Goshorn et al.

FILING DATE

June 5, 2000

GROUP ART UNIT

1642

MAR 29 2005

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AJ					
AK					
AL					
AM					
AN					

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

52	AO	Dillman, R.O., "Monoclonal Antibody Therapy for Lymphoma," <i>Cancer Practice</i> 9(2): 71-80, March/April 2001.
	AP	Schultz, J. et al., "A Tetravalent Single-chain Antibody-Streptavidin Fusion Protein for Pretargeted Lymphoma Therapy," <i>Cancer Research</i> 60: 6663-6669, December 1, 2000.
	AQ	Zhang, M. et al., "Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the $\alpha$ -emitting radionuclide, bismuth 213," <i>Blood</i> 100(1): 208-216, July 1, 2002.
	AR	Zhang, M. et al., "Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts," <i>Proc. Natl. Acad. Sci.</i> 100(4): 1891-1895, February 18, 2003.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).